Latest news & analysis
-
A Phase Ii Trial Of Onapristone In Combination With Fulvestrant For Patients With Er-Positive And Her2-Negative Metastatic Breast Cancer After Progression On Endocrine Therapy And Cdk 4/6 Inhibitors
Antiprogestins act as Progesterone Receptor (PgR) antagonists. Novel and promising class of drugs to overcome endocrine resistance associated with ESR1 mutations. SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The ...
-
Ultravist by Bayer now approved for contrast-enhanced mammography in EU
-
Mold as a Common Asthma Trigger Discussed in New Online Video
-
FPI Wishes You A Happy Chinese New Year 2023
Showcased products
Upcoming events
-
Rimini
Expodental Meeting - 2023
Get ready for the most important appointment of the year for professionals of the Italian dental ...
-
Anaheim.
The MedTech Conference
-
Paris.
The Global Advanced Materials & Surfaces International Conference (GAMS) - 2023
-
Bangkok.
3Bs Materials - 2023
Solutions for suppliers
Generate more buying requests and expand your reach by showcasing your product offering on our multi-channel platform.
- Over 4 million Visitors per year
- Over 580,000 Registered users
Learn how XPRT Premium can help you generate more leads
Add your FREE supplier profileSet up your supplier profile to get started.
Solutions for buyers
Source your project needs through our comprehensive catalog of more than 53,812 medical solutions from over 12,947 suppliers across the globe.
- Interact directly with industry suppliers.
- Match your inquiries to similar suppliers.
- Browse up-to-date product catalogs & supplier listings.
- Get notified the moment suppliers reply to your inquiry.
Try XPRT Sourcing to help you reach the right suppliers.
Open a requestWe’ll match your request to qualifying suppliers.
